Semnur lands $100M from Kazakhstan's iHolding, a step up from crypto-heavy deals
What's the deal? Semnur PharmaceuticalsDealroom has a profile for this one. Try Dealroom →, a majority-owned subsidiary of Nasdaq-listed Scilex Holding Company, has signed a binding term sheet for a proposed $100 million strategic investment from iHolding GroupDealroom has a profile for this one. Try Dealroom → LLP. The Almaty-based private investment group would buy roughly 10,000,000 newly issued Semnur shares at $10.00 each.
What does Semnur do? The Palo Alto company is a late-stage specialty pharmaceutical developer focused on non-opioid pain therapies. Its lead candidate, SEMDEXA (SP-102), is a novel gel formulation in Phase 3 for chronic radicular pain and sciatica.
What's the endgame? Proceeds would fund the ongoing Phase 3 program for SEMDEXA, plus commercialisation, acquisitions, strategic partnerships, and working capital. iHolding chairman Alain Khoueiry and chief executive officer Byron Byrd called the deal a potential "landmark transaction" that reflects "the growing capacity and international outlook of Kazakhstan-linked investment capital."
Why now? The Semnur commitment runs parallel to a separate binding term sheet at the parent level: iHolding would also invest $100 million in Scilex common stock at $15.00 per share. Both remain subject to due diligence, definitive agreements, board approvals, and other customary conditions.
The step-up: The fiat investment marks a shift for Semnur, which went public on the OTC markets in September 2025 and has since leaned on crypto-linked deals — including US$129.4M exchange of Semnur stock for bitcoin and a further $100 million stock-for-bitcoin agreement. A traditional institutional check could help validate its non-opioid pipeline after that run of financialised transactions.
What could go wrong? Nothing is final. The proposed investment hinges on customary closing conditions, including regulatory and, at the Scilex level, stockholder approvals. The companies caution the press release is not an offer to sell securities.
The signal: The paired $100 million commitments underline growing appetite from Central Asian investors for US specialty pharma and pain-management platforms — and iHolding's stated ambition to build Kazakhstan into a regional life sciences hub.
Read more: stockwatch.com, Business Insider
